Learn, Analyse & Invest
only with
only with
+91
Download Orca
Kilitch Drugs (India) Ltd.
Kilitch Drugs(India)
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹5.60 Cr.
| EX-Date | Purpose |
|---|---|
| 22 06 2021 | Audited Results |
| 13 08 2021 | Quarterly Results |
| 12 11 2021 | Quarterly Results |
| 20 12 2021 | Preferential Issue of shares & Issue Of Warrants |
| 14 02 2022 | Quarterly Results |
| 26 05 2022 | Audited Results |
| 10 08 2022 | Quarterly Results |
| 14 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 29 05 2023 | Audited Results |
| 22 07 2023 | Inter alia, to consider and approve conversion of warrants into the equity shares of the Company to the specified person only. |
| 11 08 2023 | Quarterly Results |
| 09 11 2023 | Quarterly Results |
| 08 02 2024 | Quarterly Results |
| 12 11 2024 | Quarterly Results |
| 11 02 2025 | Quarterly Results |
| 19 05 2025 | Quarterly Results & Audited Results |
| 02 07 2025 | Inter-alia transact the following; 1. To consider and approve the proposal for fund raising by way of issue of equity shares of face value of 10/-each (the ?Equity Shares?) through Rights Issue. 2. To consider and approve the deployment of the proceeds of the Right Issue. 3. To consider and approve the Draft Letter of Offer for fund raising by way of Right issue and to authorize for Application for in-principal approval for rights issue up to %50,00,00,000/- under Regulation 28(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. 4. To consider and transit any other business, if any, which may be placed before the Board with the permission of the Chairman. |
| 13 08 2025 | Quarterly Results |
| 13 11 2025 | Quarterly Results |
| 11 02 2026 | Quarterly Results & Increase in Authorised Capital & Bonus issue |
News
